Loading company…
Gaithersburg-based NexImmune is a biotech developing T cell immunotherapies built on its AIM artificial immune modulation technology.
Founded in 2011 and based in Maryland, US, NexImmune, Inc. develops T cell immunotherapies based on its AIM (artificial immune modulation) technology, designed to mimic the function of antigen-presenting cells. Its pipeline includes NEXi-001, NEXI-002 and injectable AIM, aimed at cancer, infectious disease and autoimmune disorders. Scott Carmer has been CEO since 2014, and Mathias Oelke co-founded the company. The company has had four venture rounds, including Amgen Ventures, New Enterprise Associates and Pfizer Venture Investments, and it listed on Nasdaq as NEXI in February 2021.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in